Pharmacokinetics and pharmacodynamics of oral β-lactam antibiotics as a two-dimensional approach to their efficacy

被引:26
作者
Auckenthaler, R
机构
[1] Unilabs SA, CH-1211 Geneva 1, Switzerland
[2] Univ Geneva, Geneva, Switzerland
关键词
D O I
10.1093/jac/dkf803
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pharmacokinetic and pharmacodynamic parameters are increasingly recognized as important determinants of the therapeutic efficacy of an antibiotic. For beta-lactam antibiotics, the most important determinant of the antimicrobial efficacy, and hence predictor of therapeutic efficacy, is the length of time that serum concentrations exceed the MIC. Dosing schedules for beta-lactam antibiotics should maintain serum concentrations above the MIC for the bacterial pathogen for at least 50% of the dosing interval to achieve therapeutic efficacy and prevent the development of resistance. This is a basic criterion for the clinical efficacy of beta-lactams. A combination of microbiological activity and pharmacokinetic characteristics was applied to calculate the time that serum antibiotic concentrations exceed the MIC for the major respiratory tract pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes and Klebsiella pneumoniae. In contrast with some other oral beta-lactam antibiotics, cefpodoxime 200 mg bd maintains serum concentrations above the MIC for each organism for at least 50% of the dosing interval and may therefore be an attractive choice for empirical therapy of community-acquired lower respiratory tract infections.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 20 条
[11]  
FOCHT J, 1999, ARZNEIMITTELTHERAPIE, V17, P305
[12]   COMPARISON OF CEFPODOXIME PROXETIL WITH CEFACLOR IN THE TREATMENT OF SINUSITIS [J].
GEHANNO, P ;
DEPONDT, J ;
BARRY, B ;
SIMONET, M ;
DEWEVER, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 :87-91
[13]   Management of community-acquired pneumonia in the era of pneumococcal resistance -: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group [J].
Heffelfinger, JD ;
Dowell, SF ;
Jorgensen, JH ;
Klugman, KP ;
Mabry, LR ;
Musher, DM ;
Plouffe, JF ;
Rakowsky, A ;
Schuchat, A ;
Whitney, CG .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (10) :1399-1408
[14]  
KHAN Z, 1995, 19 INT C CHEM 1995 M
[15]   Cefuroxime axetil - A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy [J].
Perry, CM ;
Brogden, RN .
DRUGS, 1996, 52 (01) :125-158
[16]   Cefixime in the treatment of patients with lower respiratory tract infections: Results of US clinical trials [J].
Quintiliani, R .
CLINICAL THERAPEUTICS, 1996, 18 (03) :373-390
[17]   PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS IN ANTIBIOTIC SELECTION, WITH PARTICULAR ATTENTION TO ORAL CEPHALOSPORINS [J].
QUINTILIANI, R ;
NIGHTINGALE, CH ;
FREEMAN, CD .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1994, 3 (01) :1-7
[18]  
*SIN ALL HLTH PART, 2000, OTOLARYNGOL HEAD NEC, V123, P5
[19]   The pharmacodynamics of β-lactams [J].
Turnidge, JD .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :10-22
[20]   CEFTIBUTEN - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND CLINICAL EFFICACY [J].
WISEMAN, LR ;
BALFOUR, JA .
DRUGS, 1994, 47 (05) :784-808